Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

@article{Morelli2018TherapeuticVO,
  title={Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.},
  author={Eugenio Morelli and Lavinia Biamonte and Cinzia Federico and Nicola Amodio and Maria Teresa Di Martino and Maria Eugenia Gallo Cantafio and Martina Manzoni and Francesca Scionti and Mehmet Kemal Samur and Annamaria Gull{\`a} and Maria Angelica Stamato and Maria Rita Pitari and Daniele Caracciolo and Settimio Sesti and Niels Morten Marslev Frandsen and Marco Rossi and Antonino Neri and Mariateresa Fulciniti and Nikhil C. Munshi and Pierosandro Tagliaferri and Pierfrancesco Tassone},
  journal={Blood},
  year={2018},
  volume={132 10},
  pages={
          1050-1063
        }
}
The microRNA (miRNA) cluster miR-17-92 is oncogenic and represents a valuable therapeutic target in c-MYC (MYC)-driven malignancies. Here, we developed novel LNA gapmeR antisense oligonucleotides (ASOs) to induce ribonuclease H-mediated degradation of MIR17HG primary transcripts and consequently prevent biogenesis of miR-17-92 miRNAs (miR-17-92s). The leading LNA ASO, MIR17PTi, impaired proliferation of several cancer cell lines (n = 48) established from both solid and hematologic tumors by on… CONTINUE READING
13
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

  • Journal of Hematology & Oncology
  • 2019
VIEW 20 EXCERPTS
CITES METHODS & BACKGROUND

Gymnotic Delivery of LNA Mixmers Targeting Viral SREs Induces HIV-1 mRNA Degradation

  • International journal of molecular sciences
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND